OBJECTIVE: Thymic carcinoma is a rare mediastinal malignant tumor, and in many patients, the tumor is detected in an inoperable advanced stage. Even when chemotherapy is administered to such patients, the patients show a poor response. We investigated new biomarkers of therapeutic molecular targets. METHODS: This study included 44 patients diagnosed and treated for primary thymic epithelial tumors at Showa University Northern Yokohama Hospital, Showa University Hospital, and Showa University Fujigaoka Hospital from 2003 to 2011. We investigated new biomarkers of therapeutic molecular targets, such as the peroxisome proliferator-activated receptor γ (PPARγ), insulin-like growth factor 1 receptor (IGF1R), epidermal growth factor receptor (EGFR), estrogen receptor (ER), progesterone receptor (PgR), androgen receptor (AR), human epidermal growth factor type 2 (HER2)/neu, CD44, and L-type amino acid transporter 1 (LAT1), in thymic tumors. RESULT: Immunohistochemical analysis showed that the PPARγ positivity rate in thymic carcinoma was 32 %, which was significantly higher than that in thymoma (4 %). The IGF1R positivity rate in thymic carcinoma was 73 %, which was significantly higher than that in thymoma (27 %). CONCLUSION: Therefore, by examining the expressions of PPARγ and IGF1R, it would be possible to identify therapy-responsive patients and to improve results of thymic carcinoma treatment.
OBJECTIVE:Thymic carcinoma is a rare mediastinal malignant tumor, and in many patients, the tumor is detected in an inoperable advanced stage. Even when chemotherapy is administered to such patients, the patients show a poor response. We investigated new biomarkers of therapeutic molecular targets. METHODS: This study included 44 patients diagnosed and treated for primary thymic epithelial tumors at Showa University Northern Yokohama Hospital, Showa University Hospital, and Showa University Fujigaoka Hospital from 2003 to 2011. We investigated new biomarkers of therapeutic molecular targets, such as the peroxisome proliferator-activated receptor γ (PPARγ), insulin-like growth factor 1 receptor (IGF1R), epidermal growth factor receptor (EGFR), estrogen receptor (ER), progesterone receptor (PgR), androgen receptor (AR), human epidermal growth factor type 2 (HER2)/neu, CD44, and L-type amino acid transporter 1 (LAT1), in thymic tumors. RESULT: Immunohistochemical analysis showed that the PPARγ positivity rate in thymic carcinoma was 32 %, which was significantly higher than that in thymoma (4 %). The IGF1R positivity rate in thymic carcinoma was 73 %, which was significantly higher than that in thymoma (27 %). CONCLUSION: Therefore, by examining the expressions of PPARγ and IGF1R, it would be possible to identify therapy-responsive patients and to improve results of thymic carcinoma treatment.
Authors: J Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; N T Sklarin; A D Seidman; C A Hudis; J Moore; P P Rosen; T Twaddell; I C Henderson; L Norton Journal: J Clin Oncol Date: 1996-03 Impact factor: 44.544
Authors: Stamatios Theocharis; Jerzy Klijanienko; Constantinos Giaginis; Jose Rodriguez; Thomas Jouffroy; Angelique Girod; Daniel Point; Gerasimos Tsourouflis; Xavier Satre-Garau Journal: J Cancer Res Clin Oncol Date: 2011-02 Impact factor: 4.553
Authors: Seena C Aisner; Suzanne Dahlberg; Meera R Hameed; David S Ettinger; Joan H Schiller; David H Johnson; Joseph Aisner; Patrick J Loehrer Journal: J Thorac Oncol Date: 2010-06 Impact factor: 15.609
Authors: T Kubota; K Koshizuka; E A Williamson; H Asou; J W Said; S Holden; I Miyoshi; H P Koeffler Journal: Cancer Res Date: 1998-08-01 Impact factor: 12.701
Authors: Paul Haluska; Heather M Shaw; Gretchen N Batzel; Donghua Yin; Julian R Molina; L Rhoda Molife; Timothy A Yap; M Luisa Roberts; Amarnath Sharma; Antonio Gualberto; Alex A Adjei; Johann S de Bono Journal: Clin Cancer Res Date: 2007-10-01 Impact factor: 12.531
Authors: Bernhard Moser; Stefan Janik; Ana-Iris Schiefer; Leonhard Müllauer; Christine Bekos; Anke Scharrer; Michael Mildner; Ferenc Rényi-Vámos; Walter Klepetko; Hendrik Jan Ankersmit Journal: PLoS One Date: 2014-04-04 Impact factor: 3.240